| Bili Wu,Bo Liu,Xueyan Jiang,Ye Yuan,Wan Qin,Kai Qin,Qi Mei,Li Zhang,Huilan Zhang,Guangyuan Hu,Xianglin Yuan. Seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with cancer and the impact of anti-tumor treatment on antibodies. Oncol Transl Med, 2021, 7: 108-114. |
| 肿瘤患者的新型冠状病毒抗体血清阳性率及抗肿瘤治疗对抗体的影响 |
| Seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with cancer and the impact of anti-tumor treatment on antibodies |
| Received:April 03, 2021 Revised:June 17, 2021 |
| DOI：10.1007/s10330-021-0488-8 |
| 中文关键词: 新型冠状肺炎；肿瘤；IgG；IgM |
| 英文关键词: coronavirus disease (COVID-19); cancer; immunoglobulin (Ig) G; IgM |
| 基金项目:国自然基金（No. 81773360, and No. 81902619），华中科技大学新冠肺炎紧急项目（No.: 2020kfyXGYJ062） |
| Author Name | Affiliation | E-mail | | Bili Wu | Department of Oncology, Tongji Hospital, Tongji Medical College, University of Science and Technology | billywu2020@outlook.com | | Bo Liu | Department of Oncology, Tongji Hospital, Tongji Medical College, University of Science and Technology | | | Xueyan Jiang | Department of Oncology, Tongji Hospital, Tongji Medical College, University of Science and Technology | | | Ye Yuan | Department of Gastroenterology, Tongji Hospital, Tongji Medical College, University of Science and Technology | | | Wan Qin | Department of Oncology, Tongji Hospital, Tongji Medical College, University of Science and Technology | | | Kai Qin | Department of Oncology, Tongji Hospital, Tongji Medical College, University of Science and Technology | | | Qi Mei | Department of Oncology, Tongji Hospital, Tongji Medical College, University of Science and Technology | | | Li Zhang | Department of Oncology, Tongji Hospital, Tongji Medical College, University of Science and Technology | | | Huilan Zhang | Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, University of Science and Technology | | | Guangyuan Hu | Department of Oncology, Tongji Hospital, Tongji Medical College, University of Science and Technology | | | Xianglin Yuan* | Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei Province, China | yuanxianglin@hust.edu.cn |
|
| Hits: 5675 |
| Download times: 6899 |
| 中文摘要: |
| 摘要：研究背景：既往研究表明新型冠状病毒更易感染肿瘤患者，并且这部分患者的预后较差。迄今为止，对肿瘤患者中新型冠状病毒感染的血清阳性率了解甚少，抗肿瘤治疗对新冠病毒抗体变化的影响尚不清楚。
患者和研究方法：在本回顾性研究中，我们纳入了2020年3月9日至4月30日在华中科技大学同济医学院附属同济医学院肿瘤科门诊就诊的肿瘤患者，记录了不同时间点的新型冠状病毒IgG和IgM血清抗体和RNA数值。
结果：我们检测了779名肿瘤患者的血清学结果，总体的新冠抗体血清阳性率（IgG和IgM）为3.4%，胃癌患者相较于其他非胃癌患者新冠抗体血清阳性率明显升高（OR值6.349[95%置信区间 2.191-18.396]）。随访提示新冠抗体血清阳性患者IgG和IgM抗体水平下降并且PCR结果保持阴性。
结论：本研究探索了武汉地区肿瘤患者感染新冠病毒的血清阳性率，肿瘤患者相比普通人群，血清阳性率近似或更低。无论是否接受抗肿瘤治疗，这部分患者的新冠抗体水平均下降。我们需要更多的研究去更好的了解抗肿瘤治疗对新冠抗体水平的影响。 |
| 英文摘要: |
| Objective: The aim of this study was to examine the seroprevalence of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) among patients with cancer and followed up changes in SARS-CoV-2-specific
antibodies to explore the impact of anti-tumor treatment in patients.
Methods: Patients with cancer who visited the Outpatient Clinic of Oncology, Tongji Hospital, Tongji
Medical College, Huazhong University of Science and Technology, Wuhan, China between March 9 and
April 30, 2020 were enrolled in this retrospective cohort study. SARS-CoV-2 immunoglobulin (Ig) G, IgM,
and viral load at various time points during the disease course were determined.
Results: We examined the serological results of 779 patients with cancer. The overall seroprevalence
(IgG-positive or IgM-positive) rate of SARS-CoV-2 was 3.4%. The probability of seropositivity was
significantly higher in patients with gastric cancer than in those without gastric cancer (odds ratio: 6.349,
95% confidence interval: 2.191–18.396). Follow-up data showed that SARS-CoV-2 IgM and IgG levels
decreased and the polymerase chain reaction test result remained negative in seropositive patients with
cancer.
Conclusion: This study investigated the seroprevalence of SARS-CoV-2 in coronavirus disease (COVID-
19)-positive patients with cancer in Wuhan, China. The seropositivity in patients with cancer was lower than
or similar to that in the general population. Irrespective of anti-tumor therapy, the levels of SARS-CoV-2
antibodies decreased in these patients. More studies are needed to better understand the impact of antitumor
therapy on change in the levels of SARS-CoV-2 antibodies. |
|
View Full Text
Download reader HTML全文 |
| Close |
|
|
|